IL2 and type 1 diabetes mellitus: Notably, immune inducers, including IL-2, are under clinical investigation, and a recent report has described a promising new IL-2 antibody, F5111.2, with single-agent activity in various preclinical non-obese diabetic (NOD) mouse models of T1D [21].